Jared T Hinkle1, Kate Perepezko2, Kelly A Mills3, Zoltan Mari4, Ankur Butala5, Ted M Dawson6, Alexander Pantelyat3, Liana S Rosenthal3, Gregory M Pontone7. 1. Medical Scientist Training Program, USA; Department of Psychiatry and Behavioral Sciences, USA; Solomon H. Snyder Department of Neuroscience, USA. Electronic address: jhinkle@jhmi.edu. 2. Department of Psychiatry and Behavioral Sciences, USA. 3. Morris K. Udall Parkinson's Disease Research Center, USA; Department of Neurology, USA. 4. Morris K. Udall Parkinson's Disease Research Center, USA; Department of Neurology, USA; Cleveland Clinic Lou Ruvo Center for Brain Health, Movement Disorders Program, Las Vegas, NV, USA. 5. Department of Psychiatry and Behavioral Sciences, USA; Morris K. Udall Parkinson's Disease Research Center, USA; Department of Neurology, USA. 6. Solomon H. Snyder Department of Neuroscience, USA; Morris K. Udall Parkinson's Disease Research Center, USA; Department of Neurology, USA; Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA. 7. Department of Psychiatry and Behavioral Sciences, USA; Morris K. Udall Parkinson's Disease Research Center, USA.
Abstract
BACKGROUND: Constipation is a prodromal feature of Parkinson's disease (PD) and the gastrointestinal (GI) tract is implicated in the pathogenesis of PD. However, no studies have demonstrated ante-mortem relationships between nigrostriatal dysfunction and GI dysautonomia in PD. METHODS: The Scale for Outcomes in Parkinson's disease for Autonomic Symptoms (SCOPA-AUT) assesses dysautonomia in the multi-center Parkinson's Progression Marker Initiative (PPMI). We used linear mixed-effects models and reliable change indices (RCIs) to examine longitudinal associations between dysautonomia and dopamine transporter (DAT) striatal binding ratios (SBRs) measured by single-photon emission computerized tomography in PPMI participants over four years (n = 397 at baseline). RESULTS: Adjusted mixed-models of longitudinal data showed that constipation-but not orthostatic hypotension or urinary dysfunction-was associated with reduced SBR in both caudate (P < 0.001) and putamen (P = 0.040). In both regions, SBR reductions between baseline and 4-year follow-up were significant and measurable (P < 0.0001), with larger decline and variance in the caudate nucleus. Four-year change in caudate-but not putaminal-SBR was significantly associated with RCI-indicated progression of GI dysautonomia (P = 0.031), but not other types of dysautonomia. These associations remained after adjusting for the use of medications or supplements to control constipation. Consistent with prior PPMI reports, motor impairment progression was not associated with SBR reduction. CONCLUSIONS: GI dysautonomia correlates with reductions in DAT availability; constipation is most closely associated with caudate-DAT reduction. Worsening GI-dysautonomia and reduced bowel movements may accompany advancing nigral degeneration or changes in nigrostriatal dopamine function.
BACKGROUND:Constipation is a prodromal feature of Parkinson's disease (PD) and the gastrointestinal (GI) tract is implicated in the pathogenesis of PD. However, no studies have demonstrated ante-mortem relationships between nigrostriatal dysfunction and GI dysautonomia in PD. METHODS: The Scale for Outcomes in Parkinson's disease for Autonomic Symptoms (SCOPA-AUT) assesses dysautonomia in the multi-center Parkinson's Progression Marker Initiative (PPMI). We used linear mixed-effects models and reliable change indices (RCIs) to examine longitudinal associations between dysautonomia and dopamine transporter (DAT) striatal binding ratios (SBRs) measured by single-photon emission computerized tomography in PPMI participants over four years (n = 397 at baseline). RESULTS: Adjusted mixed-models of longitudinal data showed that constipation-but not orthostatic hypotension or urinary dysfunction-was associated with reduced SBR in both caudate (P < 0.001) and putamen (P = 0.040). In both regions, SBR reductions between baseline and 4-year follow-up were significant and measurable (P < 0.0001), with larger decline and variance in the caudate nucleus. Four-year change in caudate-but not putaminal-SBR was significantly associated with RCI-indicated progression of GI dysautonomia (P = 0.031), but not other types of dysautonomia. These associations remained after adjusting for the use of medications or supplements to control constipation. Consistent with prior PPMI reports, motor impairment progression was not associated with SBR reduction. CONCLUSIONS:GI dysautonomia correlates with reductions in DAT availability; constipation is most closely associated with caudate-DAT reduction. Worsening GI-dysautonomia and reduced bowel movements may accompany advancing nigral degeneration or changes in nigrostriatal dopamine function.
Authors: Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl Journal: Mov Disord Date: 2015-10 Impact factor: 10.338
Authors: Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry P Moore; Mayela Rodriguez-Violante; Carlos Singer; Barbara C Tilley; Jing Huang; Glenn T Stebbins; Christopher G Goetz Journal: J Neurol Date: 2012-08-05 Impact factor: 4.849
Authors: Helen Petrovitch; Robert D Abbott; G Webster Ross; James Nelson; Kamal H Masaki; Caroline M Tanner; Lenore J Launer; Lon R White Journal: Mov Disord Date: 2009-02-15 Impact factor: 10.338
Authors: Cameron Miller-Patterson; Jesse Y Hsu; Lana M Chahine; James F Morley; Allison W Willis Journal: Clin Auton Res Date: 2022-09-03 Impact factor: 5.625
Authors: M Camacho; A D Macleod; J Maple-Grødem; J R Evans; D P Breen; G Cummins; R S Wijeyekoon; J C Greenland; G Alves; O B Tysnes; R A Lawson; R A Barker; C H Williams-Gray Journal: NPJ Parkinsons Dis Date: 2021-05-26
Authors: Dagmar N van Deursen; Odile A van den Heuvel; Jan Booij; Henk W Berendse; Chris Vriend Journal: J Neurol Date: 2020-03-12 Impact factor: 4.849